Improved Treatment for Glaucoma

  • Yeda
  • From Israel
  • Responsive
  • Patents for licensing

Summary of the technology

Glaucoma is one of the leading causes of irreversible blindness worldwide, affecting over 60 million people. It is usually caused due to raised intraocular pressure (IOP). Although several drug classes which lower IOP are available, they all cause local and systemic side effects, and improved treatments are greatly needed. The group of Prof. Steve Karlish developed new drugs derived from Digoxin, which selectively inhibit Na-K-ATPase, an ion pump that produces the eye fluids. These compounds effectively reduce ocular hypertension in various glaucoma animal models, and as such, offer a potential new therapeutic class for IOP-lowering medications.


Background and Unmet Need

Glaucoma is a common eye condition in which the optic nerve that connects the eye to the brain is damaged, usually due to raised IOP. Glaucoma can lead to irreversible blindness if it is not diagnosed and treated early, and it is a leading cause of blindness globally. Over 60 million people worldwide are estimated with glaucoma, 10% of them will lose sight in one eye.1

Since raised IOP has been implicated as the major risk factor, the main goal of all glaucoma therapies is to reduce IOP sufficiently to prevent continuous irreversible retinal cell damage. Currently available drugs, given topically or systemically, include ?-blockers, Prostaglandin analogs, ?2 adrenergic receptor agonists, Cholinergic agonists, and Carbonic anhydrase inhibitors. However, all the existing medications have local and systemic side effects, from eye burning to breathing difficulties. Moreover, over 50% of the patients require more than one drug, and a substantial portion of the patients are refractory despite maximally tolerated antiglaucoma medications (topical and/or systemic).
The fact that glaucoma remains a leading cause of blindness, despite the availability of 5 different classes of IOPlowering topical medications, suggests a great need for improved treatment options.

The Solution

Prof. Steve Karlish and his team developed novel selective inhibitors of the Na-K-ATPase pump, which is critical for the production of eye fluids.2

Technology Essence

The Na-K-ATPase consists of ? and ? subunits. Each subunit has several isoforms, differentially expressed in a tissue-specific fashion. The ?2 isoform is the predominant isoform in the epithelium in the eye. The Karlish group has developed topically-applied inhibitors that are selective for the ?2 isoform of Na-K-ATPase. These novel ?2-selective inhibitors, derivatives of Digoxin and Digitoxin, show an increased selectivity for ?2 over ?1, up to about 8-fold, making them twice more selective than Digoxin. These novel inhibitors can penetrate the intact eye and effectively reduce IOP with negligible systemic toxicity, as demonstrated in rabbits and monkeys in vivo model systems. Moreover, the derivative DcB produced a 25–30% larger reduction in basal IOP than Latanoprost, the current first-line antiglaucoma drug. Furthermore, DcB/ Latanoprost combination reduced IOP for considerably longer than DcB or Latanoprost alone (Fig. 1). Overall, this technology offers an effective reduction in ocular hypertension, the primary risk factor in glaucoma.
Fig. 1 – The effect of DcB and Latanoprost, separately and combined, on basal IOP in rabbits. RE: (A) DcB, 1mM; (B) Latanoprost, 0.005%; (C) 1 mM DcB + Latanoprost. 0.005%. Left eye (LE): PBS, control. Within each figure, the inserted symbol ? indicates the absolute difference in IOP (in mmHg) between time IOP t = 0 and the average of IOP between 3 and 8 h ± SEM. The P values refer to the difference between DcB versus Latanoprost (A) or DcB/Latanoprost versus Latanoprost (C). Points represent averages IOP/IOP t = 0 from five rabbits ± SEM.

Applications and Advantages

A treatment for glaucoma and other ocular hypertension-associated diseases ?2-selective inhibitors with negligible systemic toxicity compared to Digoxin DcB reduces IOP to a greater extent and for a longer time as compared to common antiglaucoma drugs Can be used as a monotherapy or in combination with existing antiglaucoma drugs The new agents can be synthesized in a simple process

Development Status

The Karlish lab synthesized new Digoxin derivates with improved selectivity to the ?2 isoform of the Na-K-ATPase. They characterized the Ki values for inhibition of different isoforms of the Na,K-ATPase activity by all derivates in vitro. The toxicity and efficacy of the optimal derivate were assessed in two in vivo models: normotensive rabbits and spontaneous ocular hypertensive monkeys.


1. Allison K, Patel D, Alabi O. Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future. Cureus. Published online November 24, 2020. doi:10.7759/cureus.11686 [1]
2. Katz A, Tal DM, Heller D, et al. Digoxin derivatives with selectivity for the ?2?3 isoform of Na,K-ATPase potently reduce intraocular pressure. Proc Natl Acad Sci. 2015;112(44):13723-13728. doi:10.1073/pnas.1514569112 [2]

Intellectual property status

  • Granted Patent
  • Patent application number :USA Granted: 11,077,128 USA Granted: 10,668,094 USA Granted: 9,938,316

Related Keywords

  • Biological Sciences
  • Medicine, Human Health
  • Cytology, Cancerology, Oncology
  • Biology / Biotechnology
  • Genome Research
  • Opthalmology
  • Glaucoma
  • Pharmaceuticals/fine chemicals

About Yeda

Yeda ("Knowledge" in Hebrew) Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science (WIS) and is the second company of its kind established in the world.

WIS is one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. It is located in Rehovot, Israel, just south of Tel Aviv. It was initially established as the Daniel Sieff Institute in 1934, by Israel and Rebecca Sieff of London in memory of their son Daniel. In 1949, it was renamed for Dr. Chaim Weizmann, the first President of the State of Israel and Founder of the Institute.

Yeda initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by WIS scientists. Yeda holds an exclusive agreement with WIS to market and commercialize its intellectual property and generate income to support further research and education.

Since 1959 Yeda has generated the highest income per researcher compared to any other TTO worldwide. Weizmann has generated a number of groundbreaking therapies, such as Copaxone, Rebif, Tookad, Erbitux, Vectibix, Protrazza, Humira, and recently the CAR-T cancer therapy Yescarta.

Yeda performs the following activities:

◣ Identifies and assesses research projects with commercial potential.
◣ Protects the intellectual property of WIS and its scientists.
◣ Licenses WIS' inventions and technologies to industry.
◣ Establishes new Startup companies based in WIS Intellectual Property
◣ Channels funding from industry to research projects.

Our portfolio covers a broad spectrum of the natural sciences, including:

◣ Agriculture and Plant Genetics, including Bio-fuels
◣ Chemistry and Nanotechnology
◣ Environmental Sciences and Solar Energy
◣ Mathematics and Computer Science
◣ Medical Devices
◣ Pharmaceuticals and Diagnostics
◣ Physics and Electro-Optics
◣ Research Tools


Never miss an update from Yeda

Create your free account to connect with Yeda and thousands of other innovative organizations and professionals worldwide


Send a request for information
to Yeda

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support